Journal
New England Journal of Medicine
Publication Date
7-28-2022
Volume
387
Issue
4
First Page
310
Last Page
320
Document Type
Open Access Publication
DOI
10.1056/NEJMoa2206125
Rights and Permissions
Ansell SM, Radford J, Connors JM, Długosz-Danecka M, Kim WS, Gallamini A, Ramchandren R, Friedberg JW, Advani R, Hutchings M, Evens AM, Smolewski P, Savage KJ, Bartlett NL, Eom HS, Abramson JS, Dong C, Campana F, Fenton K, Puhlmann M, Straus DJ; ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. N Engl J Med. 2022 Jul 28;387(4):310-320. doi: 10.1056/NEJMoa2206125 Copyright © 2022 Massachusetts Medical Society. Reprinted with permission.
Recommended Citation
Ansell, Stephen M; Bartlett, Nancy L; and et al., "Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma." New England Journal of Medicine. 387, 4. 310 - 320. (2022).
https://digitalcommons.wustl.edu/oa_4/1036
Additional Links
Supplemental material is available for this article at publisher site.
